QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cullinan-therapeutics-files-for-resale-of-up-to-144m-shares-by-the-selling-stockholders

- SEC Filing

 hc-wainwright--co-maintains-buy-on-cullinan-therapeutics-lowers-price-target-to-28

HC Wainwright & Co. analyst Edward White maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and lowers the price t...

 wedbush-reiterates-outperform-on-cullinan-therapeutics-maintains-36-price-target

Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and maintains $36 price tar...

 stifel-initiates-coverage-on-cullinan-therapeutics-with-buy-rating-announces-price-target-of-40

Stifel analyst Bradley Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Pric...

 why-is-cullinan-therapeutics-stock-trading-higher-on-wednesday

Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN...

 cullinan-therapeutics-to-present-clinical-data-from-phase-1-study-evaluating-novel-anti-micab-antibody-cln-619-as-monotherapy-and-in-combination-with-a-checkpoint-inhibitor-in-patients-with-advanced-solid-tumors-at-asco-2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today a...

 why-travelers-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

 btig-maintains-buy-on-cullinan-oncology-raises-price-target-to-30

BTIG analyst Kaveri Pohlman maintains Cullinan Oncology (NASDAQ:CGEM) with a Buy and raises the price target from $20 to $30.

 united-airlines-reports-upbeat-results-joins-childrens-place-interactive-brokers-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday.

 hc-wainwright--co-maintains-buy-on-cullinan-oncology-lowers-price-target-to-29

HC Wainwright & Co. analyst Edward White maintains Cullinan Oncology (NASDAQ:CGEM) with a Buy and lowers the price targe...

 why-skillsoft-shares-are-trading-lower-by-around-27-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter...

 cullinan-shifts-focus-from-oncology-to-autoimmune-disorders-raises-280m-via-equity

Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show p...

 hc-wainwright--co-maintains-buy-on-cullinan-oncology-lowers-price-target-to-29

HC Wainwright & Co. analyst Edward White maintains Cullinan Oncology (NASDAQ:CGEM) with a Buy and lowers the price targe...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION